The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs

Bibliography

• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-92
   PubMed Web of Science ®Google Scholar
• Finzi A, Colombo D, Caputo A, Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. J Eur Acad Dermatol Venereol 2007;21:1161-9
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010;146:891-5
   PubMed Web of Science ®Google Scholar
• Vena GA, Altomare G, Ayala F, Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol 2010;20:593-8
   PubMed Web of Science ®Google Scholar
• Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol 2011;146:9-15
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007;33:45-56
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84
   PubMed Web of Science ®Google Scholar
• Ammon E, Schafer C, Hofmann U, Klotz U. Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther 1996;59:503-13
   PubMed Web of Science ®Google Scholar
• Caballeria J. Current concepts in alcohol metabolism. Ann Hepatol 2003;2:60-8
   PubMedGoogle Scholar
• Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)–a review. Alcohol Clin Exp Res 1999;23:991-1007
   PubMed Web of Science ®Google Scholar
• Jimenez-Lopez JM, Cederbaum AI. CYP2E1-dependent oxidative stress and toxicity: role in ethanol-induced liver injury. Expert Opin Drug Metab Toxicol 2005;1:671-85
   PubMedGoogle Scholar
• Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol Clin Exp Res 1998;22:2125-32
   PubMed Web of Science ®Google Scholar
• Hamitouche S, Poupon J, Dreano Y, Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes. Toxicol Lett 2006;167:221-30
   PubMed Web of Science ®Google Scholar
• Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006;65:278-90
   PubMed Web of Science ®Google Scholar
• Siegmund SV, Dooley S, Brenner DA. Molecular mechanisms of alcohol-induced hepatic fibrosis. Dig Dis 2005;23:264-74
   PubMed Web of Science ®Google Scholar
• Khemawoot P, Yokogawa K, Shimada T, Miyamoto K. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats. Biochem Pharmacol 2007;73:155-62
   PubMed Web of Science ®Google Scholar
• Knockaert L, Fromenty B, Robin MA. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity. FEBS J 2011;278:4252-60
   PubMed Web of Science ®Google Scholar
• Cassano N, Vestita M, Apruzzi D, Vena GA. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol 2011;50:1323-31
   PubMed Web of Science ®Google Scholar
• Wolf R, Wolf D, Ruocco V. Alcohol intake and psoriasis. Clin Dermatol 1999;17:423-30
   PubMed Web of Science ®Google Scholar
• Gupta MA, Schork NJ, Gupta AK, Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993;28:730-2
   PubMed Web of Science ®Google Scholar
• Higgins EM, du Vivier AW. Alcohol abuse and treatment resistance in skin disease. J Am Acad Dermatol 1994;30:1048
   PubMed Web of Science ®Google Scholar
• Farkas A, Kemeny L. The alcohol metabolite acetaldehyde and psoriasis: another trigger factor? Clin Exp Dermatol 2010;35:923-5
   PubMed Web of Science ®Google Scholar
• Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155-65
   PubMed Web of Science ®Google Scholar
• Dunn LK, Gaar LR, Yentzer BA, Acitretin in dermatology: a review. J Drugs Dermatol 2011;10:772-82
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, S3 - guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012;10(Suppl 2):S1-95
   Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010;162:952-63
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Dubertret L, Ellis CN, Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150(Suppl 67):11-23
   PubMedGoogle Scholar
• Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010;63:949-74
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN, British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019
   PubMed Web of Science ®Google Scholar
• Neotigason/Soriatane. Summary of Product Characteristics
   Google Scholar
• Methotrexate. Summary of Product Characteristics
   Google Scholar
• Niwa T, Yamamoto S, Saito M, Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi 2007;127:209-16
   PubMed Web of Science ®Google Scholar
• Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36(2 Suppl):25S-32S
   PubMed Web of Science ®Google Scholar
• Larsen FG, Jakobsen P, Knudsen J, Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993;100:623-7
   PubMed Web of Science ®Google Scholar
• Chou RC, Wyss R, Huselton CA, Wiegand UW. A newly discovered xenobiotic metabolic pathway: ethyl ester formation. Life Sci 1991;49:PL169-72
   Google Scholar
• Laugier JP, de Sousa G, Bun H, Acitretin biotransformation into etretinate: role of ethanol on in vitro hepatic metabolism. Dermatology 1994;188:122-5
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann AH, Dittrich S, Saulnier E, Mechanistic studies on the ethyl-esterification of acitretin by human liver preparations in vitro. Life Sci 1995;57:PL407-12
   PubMed Web of Science ®Google Scholar
• Knights KM, Gasser R, Klemisch W. In vitro metabolism of acitretin by human liver microsomes: evidence of an acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate. Biochem Pharmacol 2000;60:507-16
   PubMed Web of Science ®Google Scholar
• Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 1998;39:S25-33
   PubMed Web of Science ®Google Scholar
• Grønhøj Larsen F, Steinkjer B, Jakobsen P, Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000;143:1164-9
   PubMed Web of Science ®Google Scholar
• Shen S, O'Brien T, Yap LM, The use of methotrexate in dermatology: a review. Australas J Dermatol 2012;53:1-18
   PubMed Web of Science ®Google Scholar
• Neuman MG, Cameron RG, Haber JA, Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem 1999;32:519-36
   PubMed Web of Science ®Google Scholar
• Jahovic N, Cevik H, Sehirli AO, Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res 2003;34:282-7
   PubMed Web of Science ®Google Scholar
• Cetiner M, Sener G, Sehirli AO, Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol 2005;209:39-50
   PubMed Web of Science ®Google Scholar
• Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-16
   PubMed Web of Science ®Google Scholar
• Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Korendowych E, Nash P, Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008;35:1454-7
   PubMed Web of Science ®Google Scholar
• Malatjalian DA, Ross JB, Williams CN, Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996;106:369-75
   Google Scholar
• Rosenberg P, Urwitz H, Johannesson A, Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-18
   PubMed Web of Science ®Google Scholar
• Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001;16:1395-401
   PubMed Web of Science ®Google Scholar
• Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-64
   PubMed Web of Science ®Google Scholar
• Miele L, Vallone S, Cefalo C, Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-86
   PubMed Web of Science ®Google Scholar
• Montaudie H, Sbidian E, Paul C, Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):12-18
   PubMed Web of Science ®Google Scholar
• Shear NH, Landau M, Malkiewicz I, Ethanol-modulated cytokine production and expression in skin cells exposed to methotrexate. Skin Pharmacol Appl Skin Physiol 1999;12:64-78
   PubMedGoogle Scholar
• Price S, James C, Deighton C. Methotrexate use and alcohol. Clin Exp Rheumatol 2010;28(5 Suppl 61):S114-16
   PubMed Web of Science ®Google Scholar
• Hamid A, Kaur J, Mahmood A. Evaluation of the kinetic properties of the folate transport system in intestinal absorptive epithelium during experimental ethanol ingestion. Mol Cell Biochem 2007;304:265-71
   PubMed Web of Science ®Google Scholar
• Hamid A, Kaur J. Decreased expression of transporters reduces folate uptake across renal absorptive surfaces in experimental alcoholism. J Membr Biol 2007;220:69-77
   PubMed Web of Science ®Google Scholar
• Hamid A, Wani NA, Kaur J. New perspectives on folate transport in relation to alcoholism-induced folate malabsorption-association with epigenome stability and cancer development. FEBS J 2009;276:2175-91
   PubMed Web of Science ®Google Scholar
• Schalinske KL, Nieman KM. Disruption of methyl group metabolism by ethanol. Nutr Rev 2005;63:387-91
   PubMed Web of Science ®Google Scholar
• Rajakulendran S, Gadsby K, Deighton C. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Musculoskeletal Care 2008;6:233-45
   PubMedGoogle Scholar
• Pincus T, Furer V, Sokka T. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol 2010;28(5 Suppl 61):S68-79
   PubMed Web of Science ®Google Scholar
• Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol Clin Exp Res 1998;22:2125-32
   PubMed Web of Science ®Google Scholar
• Qureshi S, Laganiere S, Caille G, Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. Pharm Res 1992;9:683-6
   PubMed Web of Science ®Google Scholar
• Jang GR, Harris RZ. Drug interactions involving ethanol and alcoholic beverages. Expert Opin Drug Metab Toxicol 2007;3:719-31
   PubMed Web of Science ®Google Scholar
• Paul MD, Parfrey PS, Smart M, Gault H. The effect of ethanol on serum cyclosporine A levels in renal transplant recipients. Am J Kidney Dis 1987;10:133-5
   PubMed Web of Science ®Google Scholar
• Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004;20:195-217
   PubMedGoogle Scholar
• Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62:135-42
   Web of Science ®Google Scholar
• Chan Wk, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67:3103-12
   PubMed Web of Science ®Google Scholar
• Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91
   PubMed Web of Science ®Google Scholar
• Stupans L, Tan HW, Kirlich A, Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J Pharm Pharmacol 2002;54:269-75
   PubMed Web of Science ®Google Scholar
• Tsunoda SM, Harris RZ, Christians U, Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70:462-7
   PubMed Web of Science ®Google Scholar
• Tsunoda SM, Harris RZ, Freeman RB, Warshaw A. Acute and chronic wine effects on cyclosporine (Cy A) disposition [abstract]. Br J Clin Pharmacol 2000;42
   Google Scholar
• Nyfors A, Dahl-Nyfors B, Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986;14:43-8
   PubMed Web of Science ®Google Scholar
• Smith G, Dawe RS, Clark C, Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. J Invest Dermatol 2003;121:390-8
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Altomare G, Ayala F, Safety of anti-TNFalpha agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Stelara. Summary of Product Characteristics
   Google Scholar
• Enbrel. Summary of Product Characteristics
   Google Scholar
• Yin M, Wheeler MD, Kono H, Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-52
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Sen S, Davies NA, Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52:1182-7
   PubMed Web of Science ®Google Scholar
• Boetticher NC, Peine CJ, Kwo P, A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953-60
   PubMed Web of Science ®Google Scholar
• Sharma P, Kumar A, Sharma BC, Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009;50:584-91
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Freeman AK, Chapman MS, Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-30
   PubMed Web of Science ®Google Scholar
• Milingou M, Antille C, Sorg O, Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004;140:1542-4
   PubMed Web of Science ®Google Scholar
• Monshouwer M, Witkamp RF, Nujmeijer SM, Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 1996;137:237-44
   PubMed Web of Science ®Google Scholar